Genmab says EPCORE FL-1 subgroup analysis supports epcoritamab plus R2 benefit in relapsed follicular lymphoma

• Genmab disclosed a post-hoc subgroup analysis from the Phase 3 EPCORE FL-1 trial of epcoritamab with rituximab and lenalidomide in relapsed or refractory follicular lymphoma.
• The results were presented in an oral session at the European Hematology Association 2026 Congress in Stockholm on June 11-14.
• The combination delivered consistent efficacy advantages versus rituximab-lenalidomide alone across key patient risk and fitness subgroups, with deeper responses maintained.
• Safety remained manageable across subgroups with no new safety signals, supporting fixed-duration use even when lenalidomide dosing was reduced.
• The readout strengthens the commercial case for expanding epcoritamab’s footprint in follicular lymphoma, beyond its existing approvals in other lymphoma settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20260610500156) on June 11, 2026, and is solely responsible for the information contained therein.